Abstract: The present invention provides a method, an assay and a kit for providing an indication of abnormal cell function. It was surprisingly found that the change in the serum ADAM12 concentration in individuals was useful as a prognostic tool to predict the clinical outcome, complications and mortality following an abnormal cell function. The present inventors describes ADAM12 as a overall general marker for abnormal cell function, and the present inventor for the first time demonstrate that ADAM12 is an important indicator of fetal chromosomal disease and placenta function. Specifically ADAM12 is a good marker for e.g. Downs's syndrome, trisomy 18, preeclampsia, Turner syndrome in both first and second trimester. The present inventors developed an enzyme-linked immunosorbent assay (ELISA) and a time-resolved immunofluorometric assay for the quantification of ADAM12 in serum.
Type:
Grant
Filed:
February 2, 2010
Date of Patent:
February 14, 2012
Assignees:
Statens Serum Institut, Kobenhavns Universitet, Harold Wood Hospital
Inventors:
Ulla M. Wewer, Bent Norgaard-Pedersen, Michael Christiansen, Jennie Laigaard, Camilla Frohlich
Abstract: The present invention provides a method, an assay and a kit for providing an indication of abnormal cell function. It was surprisingly found that the change in the serum ADAM12 concentration in individuals was useful as a prognostic tool to predict the clinical outcome, complications and mortality following an abnormal cell function. The present inventors describes ADAM12 as a overall general marker for abnormal cell function, and the present inventor for the first time demonstrate that ADAM12 is an important indicator of fetal chromosomal disease and placenta function. Specifically ADAM12 is a good marker for e.g. Downs's syndrome, trisomy 18, preeclampsia, Turner syndrome in both first and second trimester. The present inventors developed an enzyme-linked immunosorbent assay (ELISA) and a time-resolved immunofluorometric assay for the quantification of ADAM12 in serum.
Type:
Grant
Filed:
May 18, 2005
Date of Patent:
March 16, 2010
Assignees:
Statens Serum Institut, Kobenhavns Universitet, Harold Wood Hospital
Inventors:
Ulla M. Wewer, Bent Nørgaard-Pedersen, Michael Christiansen, Jennie Laigaard, Camilla Fröhlich, Kevin Spencer